The blood-brain barrier (BBB) is a critical interface in the neurovascular system that regulates the exchange of molecules between the peripheral circulation and the central nervous system (CNS). This pathway page covers the structural components, transport mechanisms, dysfunction in neurodegenerative diseases, and therapeutic strategies for CNS drug delivery.
The BBB is comprised of the neurovascular unit, a complex assembly of endothelial cells, pericytes, astrocytes, neurons, and microglia that work together to maintain CNS homeostasis[1]. The endothelial cells lining cerebral capillaries form the primary barrier through tight junction proteins—primarily claudin-5 and occludin—that seal the intercellular space[2].
Endothelial Cells: The cerebral endothelium differs fundamentally from peripheral vasculature. These cells exhibit continuous, non-fenestrated capillaries with extremely low pinocytic activity and high mitochondrial density to support active transport processes. The endothelial surface is coated with a glycocalyx that provides an additional layer of selectivity, acting as a molecular filter for circulating substances[3].
Pericytes: These contractile cells cover approximately 80-90% of the cerebral capillary surface area[4]. Pericytes are embedded within the basement membrane and communicate directly with endothelial cells through peg-socket contacts and paracrine signaling. They regulate capillary diameter, blood flow velocity, and the formation of tight junctions. Pericyte dysfunction is a hallmark of early BBB breakdown in neurodegenerative diseases.
Astrocytes: The astrocytic endfoot processes ensheath approximately 99% of the cerebral microvasculature[5]. These cells release trophic factors including glial cell line-derived neurotrophic factor (GDNF) and angiopoietin-1 that promote BBB formation and maintenance. The astrocyte endfeet express aquaporin-4 (AQP4) water channels that facilitate fluid movement between the blood and brain compartments, critical for glymphatic clearance.
Basement Membrane: The extracellular matrix surrounding cerebral vessels comprises collagen IV, laminin, fibronectin, and nidogen. This structural scaffold provides physical support and serves as a reservoir for growth factors. The basement membrane also participates in Aβ clearance through engagement with receptor-mediated transport systems.
The BBB develops during embryogenesis through a coordinated sequence of events. Angiopoietin-1 (ANG-1) signaling from pericytes to endothelial Tie2 receptors promotes tight junction formation. Wnt/β-catenin signaling during development is essential for BBB specification. In adults, continuous maintenance requires ongoing cross-talk between all neurovascular unit components.
The BBB expresses numerous carrier proteins that facilitate the transport of essential nutrients:
| Transporter | Substrate | Direction | Role in Neurodegeneration |
|---|---|---|---|
| GLUT1 (SLC2A1) | Glucose | Blood→Brain | Reduced in AD, impairs cerebral glucose metabolism[6] |
| LAT1 (SLC7A5) | Large neutral amino acids | Bidirectional | Transport of therapeutic amino acids[7] |
| System A (SLC38A2) | Small neutral amino acids | Blood→Brain | Altered in metabolic stress |
| CNT2 (SLC29A1) | Nucleosides | Bidirectional | Adenosine transport |
Certain molecules enter the brain via receptor-mediated transcytosis:
The ABC transporter family limits drug penetration into the brain:
These efflux transporters are major obstacles to CNS drug delivery and are often overexpressed in brain capillary endothelial cells.
BBB dysfunction is an early event in Alzheimer's disease, preceding clinical symptoms:
The glymphatic system, which depends on astrocytic aquaporin-4 water channels, is impaired with BBB breakdown, reducing clearance of Aβ and tau proteins[14].
Parkinson's disease also shows early BBB compromise:
The bidirectional relationship between BBB dysfunction and protein pathology suggests therapeutic targeting of the barrier may slow disease progression.
BBB dysfunction is also implicated in other neurodegenerative diseases:
The common theme across these conditions is that vascular dysfunction precedes or accompanies neuronal pathology, suggesting BBB preservation as a therapeutic target.
| Strategy | Mechanism | Examples |
|---|---|---|
| Pro-drug approaches | Modify drug to use endogenous transporters | L-DOPA via LAT1 |
| Nanoparticle delivery | Encapsulate drugs in BBB-crossing particles | Liposomes, polymeric nanoparticles |
| Inhibiting efflux pumps | Block P-gp to increase drug retention | Verapamil, tariquidar |
| Focused ultrasound | Transiently open BBB through mechanical disruption | Clinical trials in AD |
| Intranasal delivery | Bypass BBB via olfactory nerve pathway | Peptide therapeutics |
This technique uses focused ultrasound waves with microbubble contrast agents to temporarily disrupt tight junctions, enabling delivery of large molecules including[20]:
Clinical trials are evaluating this approach in Alzheimer's disease patients to enhance delivery of disease-modifying therapeutics.
Leveraging endogenous transport systems for drug delivery[21]:
Nanoparticle delivery systems offer multiple advantages for CNS drug delivery[22]:
Surface modification with polyethylene glycol (PEG) reduces opsonization and clearance, while ligand conjugation enables receptor-mediated targeting.
Designing BBB-penetrant drugs requires understanding the transporter requirements[23]:
These properties guide medicinal chemistry efforts to optimize CNS drug candidates.
The BBB remains the primary obstacle to effective CNS drug development. Approximately 98% of small molecule drugs and nearly 100% of large molecule drugs cannot cross the barrier in therapeutically relevant amounts[24].
Understanding BBB transport mechanisms has led to:
Active areas of BBB research include[19:1][22:1]:
BBB function can be preserved through lifestyle interventions:
These approaches offer accessible strategies for maintaining brain vascular health across the lifespan.
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. 2010. ↩︎
Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. 'Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin'. 1998. ↩︎
Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. 2003. ↩︎
Armulik A, Genové G, Mäe M, et al. Pericytes regulate the blood-brain barrier. 2010. ↩︎
Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M. Signaling at the gliovascular interface. 2003. ↩︎
Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions amplify Alzheimer's disease-type vascular dysfunction. 2015. ↩︎
Kwan T, King M, Wu D, et al. LAT1 (SLC7A5) as a target for CNS drug delivery. 2021. ↩︎
Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. 2000. ↩︎
Beffert N, Stolt PC, Herz J. Apolipoprotein E receptors in the nervous system. 2004. ↩︎
Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of drug-resistant diseases. 2005. ↩︎
Romanitan MO, Popescu BO, Winblad B, Bajenaru OA, Bogdanovic N. Occludin is overexpressed in Alzheimer's disease and vascular dementia. 2010. ↩︎
Sagare AP, Bell RD, Zhao Z, et al. Pericyte dysfunction influences amyloid-beta clearance in the aging human brain. 2011. ↩︎
Cirrito JR, Deane R, Hogan EE, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. 2005. ↩︎
Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. 2012. ↩︎
Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. 2005. ↩︎
Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. 2009. ↩︎
Zhao W, Beers DR, Appel SH. The role of immune cells in the pathogenesis of ALS. 2020. ↩︎
Waubant E. Biomarkers for disease activity in multiple sclerosis. 2021. ↩︎
Iadecola C. 'The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease'. 2017. ↩︎ ↩︎
Hersh AM, Alizadeh M, Bredno J, et al. 'Focused ultrasound for opening the blood-brain barrier in Alzheimer''s disease: current perspectives and future directions'. 2021. ↩︎
Jones AR, Shusta EV. Antibody transport into the central nervous system. 2007. ↩︎
Joshi S, Singh-Mallah R. Nanoparticle-based drug delivery for neurodegenerative disorders. 2020. ↩︎ ↩︎
Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. 'Blood-brain barrier: structural and functional properties'. 2003. ↩︎
Pardridge WM. 'The blood-brain barrier: bottleneck in brain drug development'. 2005. ↩︎
Kramer AF, Bherer L, Colcombe SJ, Dong W, Greenough WT. Environmental influences on cognitive and brain plasticity during aging. 2004. ↩︎